Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 8/20 | 0.78 |
| ▸ | MMP9 | P14780 | 7/20 | 0.78 |
| ▸ | MMP1 | P03956 | 5/20 | 0.78 |
| ▸ | MMP2 | P08253 | 5/20 | 0.78 |
| ▸ | MMP13 | P45452 | 5/20 | 0.78 |
| ▸ | MMP7 | P09237 | 1/20 | 0.78 |
| ▸ | MMP14 | P50281 | 1/20 | 0.78 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7254495 | 0.89 | MMP9 (0.84) | MMP3MMP9MMP1MMP2MMP13 | |
| SCHEMBL6554608 | 0.89 | MMP9 (0.84) | MMP3MMP9MMP1MMP2MMP13 | |
| Rebimastat SCHEMBL2379355 | 0.88 | MMP1 (1.00) | MMP3MMP9MMP1MMP2MMP13 | |
| Rebimastat SCHEMBL645121 | 0.88 | MMP1 (1.00) | MMP3MMP9MMP1MMP2MMP13 | |
| Rebimastat SCHEMBL12946005 | 0.88 | MMP1 (1.00) | MMP3MMP9MMP1MMP2MMP13 | |
| Rebimastat SCHEMBL12247619 | 0.88 | MMP1 (1.00) | MMP3MMP9MMP1MMP2MMP13 | |
| Rebimastat SCHEMBL4826862 | 0.88 | MMP1 (1.00) | MMP3MMP9MMP1MMP2MMP13 | |
| SCHEMBL12300383 | 0.84 | MMP1 (0.83) | MMP3MMP9MMP1MMP2MMP13 | |
| Rebimastat SCHEMBL12247617 | 0.83 | MMP1 (0.88) | MMP3MMP9MMP1MMP2MMP13 | |
| Rebimastat SCHEMBL12247626 | 0.83 | MMP1 (0.90) | MMP3MMP9MMP1MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20040208924-A1 | Pharmaceutical tablet having a high api content | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| US-20040175419-A1 | Control of compactibility through cystallization | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-09 | — | — | US | disclosed |
| CN-1523981-A | A pharmaceutical tablet having a high API content | ����˹�ж�-����˹˹������˾ | 2004-08-25 | — | — | CN | disclosed |
| CN-1520283-A | Control of compactability through crystallization | ����˹�ж�-����˹˹������˾ | 2004-08-11 | — | — | CN | disclosed |
| EP-1390011-A2 | CONTROL OF COMPACTABILITY THROUGH CRYSTALLIZATION | Bristol-Myers Squibb Company (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1390018-A1 | A PHARMACEUTICAL TABLET HAVING A HIGH API CONTENT | Bristol-Myers Squibb Company (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002088664-A2 | CONTROL OF COMPACTABILITY THROUGH CRYSTALLIZATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002087548-A1 | A PHARMACEUTICAL TABLET HAVING A HIGH API CONTENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040175419-A1 | Control of compactibility through cystallization | PKD1, PKD2, CALU | MMP3 2755/4885MMP9 1395/4885MMP1 564/4885 |
| US-20040208924-A1 | Pharmaceutical tablet having a high api content | TREH, SI, CYP3A5 | MMP3 3203/4885MMP9 2183/4885MMP1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.